improving understanding of relative benefits of interventions. Whilst the results of meta-analyses may be readily accessible, they are limited by the quality of the original RCTs. Systematic reviews involve the identification and qualitative assessment of all trials. We argue that systematic reviews may provide information of greater value, both to researchers and clinicians, since they illustrate the limitations of trials and ultimately of meta-analysis. 105 RCTs and four meta-analyses have failed to provide a clear answer to the question of whether selective serotonin reuptake inhibitors (SSRIs) or tricyclic/heterocyclic antidepressants should be used as first line treatment for depression in primary care settings. We will present a systematic review which examines the quality of trials and metaanalysis presenting some quantitative findings. The key findings of the systematic review are that the majority of trials are small, fail to conduct intention to treat analyses, are based in secondary care where only a minority of patients are treated, use observer rated assessments of depressive symptoms which are open to observer bias, and fail to give economic evaluations. We performed a meta-analysis using drop outs from treatment and found that overall the SSRIs had a modest advantage over tricyclics and heterocyclics (Risk Ratio 0.90; (95% CI: 0.86-0.97)). We formulated the a priori hypothesis that this effect would be strongest when older tricyclics were used as the comparison group, due to their more prominent side effects. We found that the SSRIs maintained their advantage when compared with the older tricyclics, amitriptyline and imipramine (RR 0.88; 95% CI: 0.82-0.95). When compared with newer tricyclics or heterocyclics no significant advantage for the SSRIs could be found (RR = 0.92; (95% CI: 0.82-1.04) for new tricyclics, and RR 1.02; (95% CI: 0.83-1.25) for heterocyclics). We suggest that the poor quality of many trials and these still equivocal results, based on drop out not clinical recovery, indicate a need for a large RCT based in primary care, and using a newer tricyclic as the comparison

S51. Novel antidepressants

Chairmen: H Freeman, B Leonard

CHANGES IN 5-HT RECEPTOR SENSITIVITY DURING TREATMENT WITH SSRIs: IMPLICATIONS FOR MODE OF ACTION

P.J. Cowen. University Department of Psychiatry, Littlemore Hospital, Oxford, OX4 4XN, UK

The acute pharmacological effect of selective serotonin re-uptake inhibitors (SSRIs) is essentially confined to the blockade of serotonin (5-HT) re-uptake. SSRIs are effective antidepressants and block 5-HT re-uptake a few hours after a single administration. Their antidepressant effect, however, takes several days to become apparent.

Recent animal experimental investigations have suggested that adaptive changes in 5-HT receptors may play an important role in mediating the antidepressant effects of SSRIs and, perhaps, account for the delay in onset of therapeutic effect. One popular theory suggests that acute administration of SSRIs does not increase overall 5-HT neurotransmission because activation of somatodendritic 5-HT_{1A} autoreceptors attenuates the firing of 5-HT neurones. With continued treatment, however, there is an evolving desensitisation of 5-HT_{1A} autoreceptors which permits a sustained increase in 5-HT neurotransmission. In addition, continued treatment with SSRIs

may desensitise the $5\text{-HT}_{1B/1D}$ nerve terminal autoreceptor, again facilitating 5-HT release.

Neuroendocrine studies in our laboratory with the selective 5-HT_{1A} agonist, gepirone, and the 5-HT_{1D} agonist, sumatriptan, suggest that SSRIs do indeed desensitise 5-HT_{1A} receptors, but 5-HT_{1D} receptors were unaffected. These findings are of interest in view of reports that co-administration of SSRIs with the 5-HT_{1A} receptor antagonist, pindolol, can speed the onset of antidepressant effect. Drugs that produce acute increases in 5-HT neurotransmission may therefore have an earlier onset of action than conventional antidepressant compounds.

TOLERABILITY AND SAFETY OF NOVEL ANTIDEPRESSANTS

H. Freeman. 21 Montagu Square, London, WIH 1RE, UK

As a group, the novel antidepressants (such as selective serotonin reuptake inhibitors, venlafaxine, nefazodone and mirtazapine) compared to older tricyclics show substantially lower incidences of adverse events in general, and improved safety due to a reduction of anticholinergic side effects. This finding is consistent with the fact that novel antidepressants are developed to be more selective in their mechanism of action. In the case of the SSRIs, the pharmacological action is exerted almost exclusively via the serotonergic (5-HT) system. However, their non-specific actions at receptor level, through stimulation of all 5-HT receptors, give rise to a variety of typical side effects, namely gastrointestinal side effects such as nausea and vomiting, headache, insomnia, restlessness and symptoms of sexual dysfunction. Venlafaxine inhibits reuptake of both noradrenaline (NA) and 5-HT, but because of a lack of receptor-specific actions its side effect profile still shows similarities with both the TCAs and SSRIs. Nefazodone, in addition to inhibiting 5-HT reuptake, specifically blocks 5-HT2 receptors. This profile results in substantial reduction of 5-HT2-mediated side effects, namely nervousness, insomnia, diarrhoea and sexual dysfunction. Mirtazapine combines enhancement of both NA and 5-HT neurotransmission by blocking α₂ adrenoceptors with specific blockade of 5-HT₂ and 5-HT₃ receptors. As a result, the incidences of anti-adrenergic and serotonergic side effects are comparable to placebo. Transient initial somnolence can be related to its antihistaminergic properties. In conclusion, the selective receptor actions of new antidepressants result in a substantial improvement in their overall tolerability and safety. The data suggest that the receptor-specific antidepressants which will become available throughout Europe during the years to come show a significantly better tolerability profile which may improve compliance and decrease the burden of pharmacological therapy without influencing efficacy.

NEW TRENDS IN THE PHARMACOLOGICAL TREATMENT OF DEPRESSION

B.E. Leonard. Department of Pharmacology, University College, Galway, Ireland

The need to develop new antidepressants has been motivated by the frequency and potential severity of the adverse effects of the tricyclic and monoamine oxidase inhibitor antidepressants. This search for new classes of antidepressants has led to the development of selective inhibitors of noradrenaline or serotonin (5-hydroxytryptamine; 5-HT) reuptake, reversible inhibitors of monoamine oxidase, and noradrenergic and specific serotonergic antidepressants. More recently, novel antidepressants such as mirtazapine, which modulate both noradrenergic and different populations of 5-HT receptors, have been developed. However, while such novel antidepressants have different pharmacological profiles, there is no evidence that their therapeutic